Clinical Data

Graphic image of an arrow nailing the bullseye of a target
Biotech

Cogent hits primary endpoint, building case for Blueprint rival

The phase 3 trial has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.
Nick Paul Taylor Jul 7, 2025 9:16am
An arrow incrementally going up stairs before pointing straight up Blue background

Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win

Jul 2, 2025 9:53am
long shot miss basketball hoop fail shoot

Organon axes 'biggest potential opportunity' after trial fail

Jul 2, 2025 8:43am
Close up shot of the target from a dart game

Amgen, Zai say stomach cancer candidate hits phase 3 mark

Jun 30, 2025 10:36am
failure crash no fail rocket cancelled end

INmune flunks Alzheimer’s trial, focuses on subgroup efficacy

Jun 30, 2025 8:50am
success failure signposts

Alto's phase 2 depression trial misses primary efficacy endpoint

Jun 26, 2025 9:28am